Ryusuke Shodo1, Keisuke Yamazaki2, Yushi Ueki2, Takeshi Takahashi2, Arata Horii2. 1. Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahi-machi, Chuo-ku, Niigata, 951-8510, Japan. ryusuke.s.0415@gmail.com. 2. Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahi-machi, Chuo-ku, Niigata, 951-8510, Japan.
Abstract
PURPOSE: Sarcopenia, defined as a decrease in the skeletal muscle mass and its function, is associated with a poor clinical outcome in several malignancies. We aimed to examine whether sarcopenia can be a predictor of incompletion of concurrent chemoradiotherapy (CCRT) and survival for head and neck cancer (HNC) patients. METHODS: Forty-one male HNC patients who received CCRT were enrolled in the study. Cross-sectional muscle areas at the third lumbar vertebral level were normalized by the squared height of the patients and were termed the lumbar skeletal muscle index (LSMI, cm2/m2), a marker of sarcopenia. Patients were divided into high (30/41, 73%) and low (11/41, 27%) LSMI groups. The LSMI cut-off value was set at 39.7 cm2/m2 based on a receiver operating characteristic curve for incompletion of CCRT. The groups were compared for survival rate by the Kaplan-Meier method. Factors predicting incompletion of CCRT were investigated among several variables. RESULTS: Multivariate analysis showed that a pre-treatment low LSMI (P = 0.033) and age over 70 years (P = 0.023) were the only significant predictors for incompletion of CCRT. The 2-year disease-specific survival (DSS) rate was significantly lower in the low LSMI group (61%) than in the high LSMI group (97%, P = 0.012), whereas there were no differences in the DSS rate between the low and high body mass index groups. CONCLUSION: The prevalence of sarcopenia in HNC patients receiving CCRT was 27%. Its presence before treatment was a significant predictor of incomplete CCRT and poor DSS rate in HNC patients.
PURPOSE:Sarcopenia, defined as a decrease in the skeletal muscle mass and its function, is associated with a poor clinical outcome in several malignancies. We aimed to examine whether sarcopenia can be a predictor of incompletion of concurrent chemoradiotherapy (CCRT) and survival for head and neck cancer (HNC) patients. METHODS: Forty-one male HNCpatients who received CCRT were enrolled in the study. Cross-sectional muscle areas at the third lumbar vertebral level were normalized by the squared height of the patients and were termed the lumbar skeletal muscle index (LSMI, cm2/m2), a marker of sarcopenia. Patients were divided into high (30/41, 73%) and low (11/41, 27%) LSMI groups. The LSMI cut-off value was set at 39.7 cm2/m2 based on a receiver operating characteristic curve for incompletion of CCRT. The groups were compared for survival rate by the Kaplan-Meier method. Factors predicting incompletion of CCRT were investigated among several variables. RESULTS: Multivariate analysis showed that a pre-treatment low LSMI (P = 0.033) and age over 70 years (P = 0.023) were the only significant predictors for incompletion of CCRT. The 2-year disease-specific survival (DSS) rate was significantly lower in the low LSMI group (61%) than in the high LSMI group (97%, P = 0.012), whereas there were no differences in the DSS rate between the low and high body mass index groups. CONCLUSION: The prevalence of sarcopenia in HNC patients receiving CCRT was 27%. Its presence before treatment was a significant predictor of incomplete CCRT and poor DSS rate in HNC patients.
Entities:
Keywords:
Chemoradiotherapy; Cisplatin; Head and neck; Sarcopenia; Skeletal muscle
Authors: J Arends; V Baracos; H Bertz; F Bozzetti; P C Calder; N E P Deutz; N Erickson; A Laviano; M P Lisanti; D N Lobo; D C McMillan; M Muscaritoli; J Ockenga; M Pirlich; F Strasser; M de van der Schueren; A Van Gossum; P Vaupel; A Weimann Journal: Clin Nutr Date: 2017-06-23 Impact factor: 7.324
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: O Huillard; O Mir; M Peyromaure; C Tlemsani; J Giroux; P Boudou-Rouquette; S Ropert; N Barry Delongchamps; M Zerbib; F Goldwasser Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640
Authors: Sandra I Bril; Abrahim Al-Mamgani; Najiba Chargi; Peter Remeijer; Lot A Devriese; Jan Paul de Boer; Remco de Bree Journal: Head Neck Date: 2021-10-29 Impact factor: 3.821
Authors: Aniek T Zwart; Wolf Pörtzgen; Irene van Rijn-Dekker; Grigory A Sidorenkov; Rudi A J O Dierckx; Roel J H M Steenbakkers; Inge Wegner; Anouk van der Hoorn; Geertruida H de Bock; Gyorgy B Halmos Journal: J Clin Med Date: 2022-08-09 Impact factor: 4.964